Scott McNitt
Concepts (302)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Defibrillators, Implantable | 51 | 2004 | 35 |
Why?
| Long QT Syndrome | 29 | 2005 | 35 |
Why?
| Death, Sudden, Cardiac | 30 | 2004 | 31 |
Why?
| Ventricular Dysfunction, Left | 21 | 2004 | 35 |
Why?
| Myocardial Infarction | 26 | 2005 | 129 |
Why?
| Tachycardia, Ventricular | 17 | 2004 | 25 |
Why?
| Heart Failure | 19 | 2004 | 106 |
Why?
| Electrocardiography | 35 | 2005 | 132 |
Why?
| Cardiac Resynchronization Therapy | 10 | 2010 | 8 |
Why?
| Ventricular Fibrillation | 12 | 2004 | 24 |
Why?
| Proportional Hazards Models | 28 | 2004 | 123 |
Why?
| Ether-A-Go-Go Potassium Channels | 7 | 2006 | 9 |
Why?
| Heart Arrest | 12 | 2004 | 37 |
Why?
| KCNQ1 Potassium Channel | 6 | 2007 | 13 |
Why?
| Risk Factors | 46 | 2004 | 555 |
Why?
| Male | 93 | 1980 | 1553 |
Why?
| Female | 92 | 2004 | 1643 |
Why?
| Adrenergic beta-Antagonists | 16 | 2005 | 47 |
Why?
| Romano-Ward Syndrome | 5 | 2007 | 7 |
Why?
| Risk Assessment | 27 | 2004 | 324 |
Why?
| Aged | 54 | 2004 | 988 |
Why?
| Electric Countershock | 8 | 2004 | 24 |
Why?
| Middle Aged | 54 | 2004 | 1161 |
Why?
| Atrial Fibrillation | 6 | 2006 | 40 |
Why?
| Humans | 98 | 1978 | 1856 |
Why?
| Treatment Outcome | 29 | 2004 | 661 |
Why?
| Heart Conduction System | 7 | 2004 | 37 |
Why?
| European Continental Ancestry Group | 5 | 2006 | 117 |
Why?
| Syncope | 11 | 2006 | 24 |
Why?
| Genotype | 14 | 2007 | 175 |
Why?
| Genetic Predisposition to Disease | 11 | 2006 | 131 |
Why?
| Mutation | 7 | 2006 | 340 |
Why?
| African Continental Ancestry Group | 3 | 2006 | 80 |
Why?
| Kaplan-Meier Estimate | 14 | 2007 | 89 |
Why?
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2009 | 7 |
Why?
| Hemostasis, Surgical | 1 | 2008 | 11 |
Why?
| Punctures | 1 | 2008 | 22 |
Why?
| Coagulants | 1 | 2008 | 12 |
Why?
| Heart Rate | 11 | 2005 | 138 |
Why?
| Angioplasty, Balloon, Coronary | 1 | 2008 | 29 |
Why?
| Follow-Up Studies | 24 | 2004 | 553 |
Why?
| Femoral Artery | 1 | 2008 | 52 |
Why?
| Mutation, Missense | 4 | 2007 | 59 |
Why?
| Adult | 33 | 2005 | 1317 |
Why?
| Arrhythmias, Cardiac | 7 | 2004 | 65 |
Why?
| Hemorrhage | 1 | 2008 | 103 |
Why?
| Survival Analysis | 17 | 2004 | 205 |
Why?
| Registries | 12 | 2006 | 83 |
Why?
| Prospective Studies | 14 | 2005 | 545 |
Why?
| Prognosis | 17 | 2004 | 388 |
Why?
| Young Adult | 10 | 2008 | 380 |
Why?
| Heart Diseases | 1 | 2006 | 92 |
Why?
| Adolescent | 18 | 2005 | 891 |
Why?
| Survival Rate | 14 | 2005 | 250 |
Why?
| Phenotype | 8 | 2006 | 303 |
Why?
| Retrospective Studies | 15 | 2004 | 653 |
Why?
| Cause of Death | 6 | 2004 | 82 |
Why?
| Electrocardiography, Ambulatory | 5 | 2007 | 23 |
Why?
| Child | 13 | 2006 | 749 |
Why?
| Time Factors | 14 | 2004 | 896 |
Why?
| Incidence | 9 | 2006 | 336 |
Why?
| Aza Compounds | 4 | 2006 | 13 |
Why?
| Quinolines | 4 | 2006 | 26 |
Why?
| Chi-Square Distribution | 7 | 2006 | 179 |
Why?
| Echocardiography | 6 | 2007 | 93 |
Why?
| Stroke Volume | 9 | 2005 | 54 |
Why?
| Child, Preschool | 11 | 2006 | 554 |
Why?
| Infant | 10 | 2006 | 464 |
Why?
| Jervell-Lange Nielsen Syndrome | 2 | 2006 | 5 |
Why?
| Diabetes Mellitus | 2 | 2009 | 72 |
Why?
| Myocardial Ischemia | 4 | 2005 | 62 |
Why?
| Sodium Channels | 2 | 2008 | 32 |
Why?
| Catheter Ablation | 2 | 2009 | 38 |
Why?
| Sequence Deletion | 2 | 2007 | 88 |
Why?
| Muscle Proteins | 2 | 2008 | 56 |
Why?
| Codon, Nonsense | 2 | 2007 | 15 |
Why?
| Membrane Potentials | 2 | 2007 | 99 |
Why?
| United States | 7 | 2005 | 604 |
Why?
| Recurrence | 8 | 2006 | 261 |
Why?
| Anti-Arrhythmia Agents | 2 | 2006 | 36 |
Why?
| Cardiovascular Diseases | 4 | 2004 | 127 |
Why?
| Models, Molecular | 2 | 2007 | 102 |
Why?
| Logistic Models | 6 | 2004 | 251 |
Why?
| Anti-Infective Agents | 4 | 2006 | 54 |
Why?
| Polymorphism, Genetic | 2 | 2006 | 94 |
Why?
| Cohort Studies | 9 | 2004 | 332 |
Why?
| Sex Factors | 7 | 2005 | 284 |
Why?
| Age Distribution | 6 | 2007 | 127 |
Why?
| Ventricular Remodeling | 2 | 2011 | 21 |
Why?
| Multicenter Studies as Topic | 4 | 2004 | 70 |
Why?
| Infant, Newborn | 5 | 2007 | 389 |
Why?
| Ventricular Dysfunction, Right | 2 | 2009 | 11 |
Why?
| Canada | 2 | 2009 | 60 |
Why?
| Smoking | 2 | 2006 | 153 |
Why?
| Multivariate Analysis | 6 | 2008 | 225 |
Why?
| Heart | 2 | 2010 | 88 |
Why?
| Torsades de Pointes | 2 | 2008 | 16 |
Why?
| Cardiac Resynchronization Therapy Devices | 1 | 2011 | 4 |
Why?
| Cardiac Pacing, Artificial | 2 | 2010 | 27 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 34 |
Why?
| Menopause | 1 | 2011 | 27 |
Why?
| Age of Onset | 2 | 2007 | 64 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2004 | 176 |
Why?
| Myocardial Contraction | 1 | 2011 | 52 |
Why?
| Heterozygote | 2 | 2007 | 80 |
Why?
| Heart Block | 1 | 2011 | 30 |
Why?
| Electrodes, Implanted | 1 | 2011 | 31 |
Why?
| Hypothermia, Induced | 1 | 2010 | 16 |
Why?
| Severity of Illness Index | 6 | 2005 | 358 |
Why?
| Autonomic Nervous System | 1 | 2010 | 41 |
Why?
| Electrophysiologic Techniques, Cardiac | 2 | 2005 | 11 |
Why?
| Diagnosis, Computer-Assisted | 2 | 2007 | 39 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2007 | 39 |
Why?
| Death | 1 | 2010 | 21 |
Why?
| Delayed Rectifier Potassium Channels | 2 | 2006 | 8 |
Why?
| Heart Atria | 1 | 2010 | 37 |
Why?
| Cardiomegaly | 1 | 2010 | 36 |
Why?
| Ventricular Function, Right | 2 | 2005 | 15 |
Why?
| Protein Structure, Secondary | 1 | 2009 | 54 |
Why?
| Ion Channel Gating | 1 | 2011 | 42 |
Why?
| Glomerular Filtration Rate | 2 | 2006 | 33 |
Why?
| Predictive Value of Tests | 5 | 2005 | 321 |
Why?
| Coronary Artery Bypass | 1 | 2010 | 46 |
Why?
| Cardiology | 1 | 2010 | 25 |
Why?
| Early Ambulation | 1 | 2008 | 4 |
Why?
| Aged, 80 and over | 7 | 2006 | 599 |
Why?
| Ventricular Dysfunction | 1 | 2008 | 8 |
Why?
| Angiography | 1 | 2009 | 63 |
Why?
| Body Mass Index | 1 | 2010 | 122 |
Why?
| Sotalol | 1 | 2008 | 6 |
Why?
| Acetanilides | 1 | 2008 | 6 |
Why?
| Administration, Topical | 1 | 2008 | 57 |
Why?
| Conserved Sequence | 1 | 2009 | 73 |
Why?
| Pressure | 1 | 2008 | 79 |
Why?
| Models, Biological | 2 | 2011 | 410 |
Why?
| Asian Continental Ancestry Group | 1 | 2008 | 23 |
Why?
| Adrenergic beta-Agonists | 1 | 2008 | 39 |
Why?
| Sex Distribution | 4 | 2007 | 101 |
Why?
| Siblings | 1 | 2008 | 28 |
Why?
| Tachycardia, Supraventricular | 1 | 2008 | 14 |
Why?
| Atrial Flutter | 1 | 2008 | 11 |
Why?
| Statistics, Nonparametric | 4 | 2004 | 141 |
Why?
| Piperazines | 1 | 2008 | 57 |
Why?
| Physicians | 1 | 2010 | 104 |
Why?
| Medical History Taking | 1 | 2008 | 53 |
Why?
| Cholesterol Ester Transfer Proteins | 1 | 2007 | 9 |
Why?
| Genetic Variation | 1 | 2008 | 91 |
Why?
| Risk | 4 | 2004 | 203 |
Why?
| African Americans | 1 | 2010 | 108 |
Why?
| Frameshift Mutation | 1 | 2007 | 20 |
Why?
| RNA Splice Sites | 1 | 2007 | 14 |
Why?
| Japan | 1 | 2007 | 25 |
Why?
| Netherlands | 1 | 2007 | 16 |
Why?
| Aryldialkylphosphatase | 1 | 2007 | 6 |
Why?
| Sodium | 1 | 2008 | 96 |
Why?
| Pregnancy, High-Risk | 1 | 2007 | 12 |
Why?
| Mutagenesis, Insertional | 1 | 2007 | 37 |
Why?
| Ion Transport | 1 | 2007 | 42 |
Why?
| Coronary Artery Disease | 1 | 2008 | 56 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2007 | 28 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 145 |
Why?
| Hospitalization | 5 | 2004 | 169 |
Why?
| Angiotensinogen | 1 | 2006 | 8 |
Why?
| Primary Prevention | 1 | 2007 | 44 |
Why?
| Bundle-Branch Block | 3 | 2011 | 17 |
Why?
| Physician's Practice Patterns | 1 | 2010 | 149 |
Why?
| Kidney | 1 | 2010 | 223 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2007 | 31 |
Why?
| Mental Health | 1 | 2007 | 43 |
Why?
| Attitude of Health Personnel | 1 | 2010 | 165 |
Why?
| Protein Transport | 1 | 2007 | 101 |
Why?
| Myocardial Revascularization | 1 | 2006 | 18 |
Why?
| Pregnancy Outcome | 1 | 2007 | 54 |
Why?
| Potassium | 1 | 2007 | 98 |
Why?
| Kidney Failure, Chronic | 1 | 2007 | 57 |
Why?
| Flecainide | 1 | 2005 | 8 |
Why?
| DNA | 1 | 2011 | 262 |
Why?
| Tachycardia | 1 | 2005 | 32 |
Why?
| Age Factors | 4 | 2006 | 480 |
Why?
| Protein Structure, Tertiary | 1 | 2007 | 163 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 34 |
Why?
| Diabetes Complications | 1 | 2005 | 49 |
Why?
| Blood Pressure | 1 | 2007 | 205 |
Why?
| Asthma | 1 | 2008 | 97 |
Why?
| New York | 4 | 2005 | 422 |
Why?
| Obesity | 1 | 2007 | 149 |
Why?
| Hypertension | 1 | 2006 | 161 |
Why?
| Odds Ratio | 3 | 2004 | 157 |
Why?
| Probability | 3 | 2004 | 190 |
Why?
| Sensitivity and Specificity | 3 | 2006 | 427 |
Why?
| Cardiomyopathies | 2 | 2010 | 43 |
Why?
| Systole | 2 | 2009 | 31 |
Why?
| Equipment Failure | 2 | 2008 | 44 |
Why?
| Blood Urea Nitrogen | 2 | 2005 | 30 |
Why?
| Clinical Trials as Topic | 3 | 2004 | 251 |
Why?
| Electrophysiology | 2 | 2005 | 101 |
Why?
| Regression Analysis | 2 | 2007 | 256 |
Why?
| Reproducibility of Results | 2 | 2007 | 391 |
Why?
| Pacemaker, Artificial | 2 | 2008 | 29 |
Why?
| Life Tables | 2 | 2004 | 33 |
Why?
| Algorithms | 2 | 2007 | 226 |
Why?
| Disease Progression | 2 | 2004 | 244 |
Why?
| Echocardiography, Doppler | 1 | 2011 | 20 |
Why?
| Estrogen Replacement Therapy | 1 | 2011 | 21 |
Why?
| Cardiotoxins | 1 | 2011 | 3 |
Why?
| Europe | 1 | 2011 | 54 |
Why?
| Neuromuscular Nondepolarizing Agents | 1 | 2011 | 10 |
Why?
| Minnesota | 1 | 2010 | 22 |
Why?
| Drug Evaluation, Preclinical | 1 | 2011 | 65 |
Why?
| Blood Volume | 1 | 2010 | 35 |
Why?
| Ventricular Function, Left | 1 | 2011 | 41 |
Why?
| World Health | 1 | 2011 | 41 |
Why?
| Arousal | 1 | 2010 | 37 |
Why?
| Monitoring, Physiologic | 1 | 2010 | 81 |
Why?
| Blood Circulation | 1 | 2010 | 26 |
Why?
| DNA Mutational Analysis | 1 | 2011 | 110 |
Why?
| Creatinine | 1 | 2010 | 69 |
Why?
| Exercise Test | 1 | 2010 | 51 |
Why?
| Guidelines as Topic | 1 | 2011 | 77 |
Why?
| Echocardiography, Transesophageal | 1 | 2010 | 33 |
Why?
| Xenopus laevis | 1 | 2011 | 49 |
Why?
| Oocytes | 1 | 2011 | 45 |
Why?
| Heart Ventricles | 1 | 2011 | 86 |
Why?
| Obesity, Morbid | 1 | 2010 | 28 |
Why?
| Ion Channels | 1 | 2010 | 61 |
Why?
| Organ Size | 1 | 2010 | 118 |
Why?
| Guideline Adherence | 1 | 2010 | 64 |
Why?
| Drug Therapy, Combination | 2 | 1978 | 189 |
Why?
| Exercise | 1 | 2010 | 82 |
Why?
| Computer Simulation | 1 | 2011 | 134 |
Why?
| Kidney Diseases | 1 | 2011 | 90 |
Why?
| Continental Population Groups | 1 | 2010 | 85 |
Why?
| Health Care Surveys | 1 | 2010 | 91 |
Why?
| Physicians, Family | 1 | 2010 | 66 |
Why?
| Referral and Consultation | 1 | 2010 | 134 |
Why?
| Computational Biology | 1 | 2009 | 39 |
Why?
| Ventricular Premature Complexes | 1 | 2008 | 11 |
Why?
| Angina Pectoris | 1 | 2008 | 31 |
Why?
| Patient Selection | 1 | 2010 | 155 |
Why?
| Discriminant Analysis | 1 | 2007 | 21 |
Why?
| Hospital Mortality | 1 | 2008 | 60 |
Why?
| Point Mutation | 1 | 2008 | 122 |
Why?
| Postpartum Period | 1 | 2007 | 32 |
Why?
| Aspartic Acid | 1 | 2007 | 37 |
Why?
| Lipids | 1 | 2007 | 97 |
Why?
| Parity | 1 | 2007 | 28 |
Why?
| Glutamine | 1 | 2007 | 27 |
Why?
| Combined Modality Therapy | 1 | 2008 | 219 |
Why?
| Threonine | 1 | 2006 | 27 |
Why?
| Practice Guidelines as Topic | 1 | 2010 | 174 |
Why?
| Methionine | 1 | 2006 | 38 |
Why?
| Gene Frequency | 1 | 2006 | 42 |
Why?
| Confidence Intervals | 1 | 2007 | 104 |
Why?
| Homozygote | 1 | 2006 | 68 |
Why?
| Arginine | 1 | 2007 | 57 |
Why?
| Glutamic Acid | 1 | 2007 | 66 |
Why?
| ROC Curve | 1 | 2006 | 80 |
Why?
| Nebraska | 1 | 2005 | 6 |
Why?
| Models, Cardiovascular | 1 | 2006 | 40 |
Why?
| Gestational Age | 1 | 2007 | 114 |
Why?
| Biological Markers | 1 | 2008 | 262 |
Why?
| Metoprolol | 1 | 2005 | 7 |
Why?
| Propanolamines | 1 | 2005 | 12 |
Why?
| Atenolol | 1 | 2005 | 10 |
Why?
| Placebo Effect | 1 | 2005 | 26 |
Why?
| Enzyme Inhibitors | 1 | 2008 | 216 |
Why?
| Carbazoles | 1 | 2005 | 21 |
Why?
| Equipment Failure Analysis | 1 | 2005 | 44 |
Why?
| Placebos | 1 | 2006 | 110 |
Why?
| Mortality | 1 | 2006 | 50 |
Why?
| Survivors | 1 | 2006 | 45 |
Why?
| Equipment Design | 1 | 2006 | 132 |
Why?
| Outcome Assessment (Health Care) | 1 | 2008 | 163 |
Why?
| Amino Acid Sequence | 1 | 2009 | 319 |
Why?
| Analysis of Variance | 1 | 2007 | 339 |
Why?
| Action Potentials | 1 | 2006 | 77 |
Why?
| Tomography, X-Ray Computed | 1 | 2010 | 321 |
Why?
| Smoking Cessation | 1 | 2006 | 46 |
Why?
| Prevalence | 1 | 2007 | 281 |
Why?
| Research Design | 1 | 2006 | 169 |
Why?
| Comorbidity | 1 | 2005 | 190 |
Why?
| Molecular Sequence Data | 1 | 2009 | 404 |
Why?
| Quality of Life | 1 | 2007 | 188 |
Why?
| Coronary Disease | 1 | 2006 | 94 |
Why?
| Double-Blind Method | 1 | 2005 | 274 |
Why?
| Pregnancy | 1 | 2007 | 455 |
Why?
| Doxorubicin | 2 | 1978 | 60 |
Why?
| Daunorubicin | 1 | 1980 | 10 |
Why?
| Neoplasms, Experimental | 1 | 1980 | 72 |
Why?
| Leukemia, Lymphoid | 1 | 1978 | 22 |
Why?
| Cyclophosphamide | 1 | 1978 | 82 |
Why?
| Animals | 3 | 1978 | 1031 |
Why?
| Leukemia, Experimental | 2 | 1978 | 20 |
Why?
| Melanoma | 1 | 1980 | 87 |
Why?
| Cell Survival | 1 | 1980 | 229 |
Why?
| DNA, Neoplasm | 1 | 1978 | 75 |
Why?
| Mice | 2 | 1978 | 623 |
Why?
| Cell Count | 1 | 1978 | 163 |
Why?
| Drug Administration Schedule | 1 | 1978 | 191 |
Why?
| Kinetics | 1 | 1980 | 349 |
Why?
| Bone Marrow | 1 | 1978 | 109 |
Why?
| Cell Line | 1 | 1980 | 375 |
Why?
|
|
McNitt's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
